

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH GROUP INC.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

RESUMPTION GUIDANCE

This announcement is made by China Health Group Inc. (the “**Company**”) pursuant to Rules 17.10 and 17.26A of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions under Part XIVA of the Securities and Futures ordinance (Chapter 571 of the Laws of Hong Kong).

Reference are made to the announcements of the Company dated 13 March 2019, 22 March 2019, 1 April 2019 and 15 May 2019 (the “**Announcements**”), respectively, in relation to, among others things, delay in publication of the 2018 Annual Results and despatch of the 2018 Annual Report as well as delay in publication of the 2019 First Quarterly Results and despatch of the 2019 First Quarterly Report. Terms used herein shall have the same meanings as defined in the Announcements unless the context requires otherwise.

On 15 May 2019, the Company received a letter from the Stock Exchange (the “**Letter**”), in which the Stock Exchange sets out the following resumption guidance (the “**Resumption Guidance**”) for the Company:

- a. publish all outstanding financial results required under the Listing Rules and address any audit modifications; and
- b. announce all material information of the Company for its shareholders and other investors to appraise its position.

The Letter also states that the Company must remedy the issues causing its trading suspension and fully comply with the Rules to the Exchange's satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. To assist the Company, the Stock Exchange has set out the resumption guidance which it may modify or supplement if the Company's situation changes.

The Stock Exchange further provided the following resumption guidance in the Letter:

Under Rule 9.14A(1), the Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 12 months. In the case of the Company, the 12 month period expires on 30 March 2020. If the Company fails to remedy the issues causing its trading suspension, fully comply with the Rules to the Exchange's satisfaction and resume trading in its shares by 30 March 2020, the Listing Department will recommend the GEM Listing Committee to proceed with the cancellation of the Company's listing. Under GEM Rule 9.15, the Exchange also has the right to impose a shorter specific remedial period, where appropriate.

The Company is taking appropriate steps to resolve the issues causing its trading suspension and will seek to resume trading of its shares as soon as possible. The Company will keep the Shareholders and the public informed of the latest developments by making further announcement(s) as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended since 9:00 a.m. on 1 April 2019 and will continue to be suspended until further notice.

By order of the Board

China Health Group Inc.

William Xia GUO

Chairman

Hong Kong, 21 May 2019

As at the date hereof, the Board comprises two executive directors, being Mr. William Xia GUO and Dr. Maria Xue Mei SONG; one non-executive director, being Mr. Michael SU; and four independent non-executive directors, being Mr. Rui QIU, Dr. Bin Hui Ni, Mr. Mark Gavin LOTTER and Mr. Ling ZHEN.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made

all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the "Latest Company Announcements" page for at least 7 days from the date of its posting and on the Company's website at www.chgi.net.